EXCLUSIVE: Acting FDA Commissioner says he's pro-life, regrets past entanglement with Planned Parenthood

First on Live Action News, Acting FDA Commissioner Kyle Diamantas spoke with Live Action founder and president Lila Rose about his regret over his past work as an outside attorney for Planned Parenthood.

Key Takeaways:

Acting FDA Commissioner Kyle Diamantas spoke to Live Action founder and president Lila Rose by phone about his regret over his past legal involvement with Planned Parenthood.
Diamantas stated that he was an attorney in private practice in Florida when he was assigned to a case involving Planned Parenthood of Greater Orlando. He later came to regret his involvement and asked his superiors that he be removed from the case.
Diamantas says he is pro-life and cares about the pro-life cause, and that his moral opposition to abortion is what led him to ask for removal from the case in Florida.
Diamantas told Rose that reviewing the abortion pill remains a top priority for the administration and for him.

The Details:

Past Planned Parenthood involvement

Speaking by phone with Lila Rose on May 13, 2026, Diamantas stated that he regrets his past involvement as an attorney in Planned Parenthood of Greater Orlando v. MMB Properties, saying he was assigned to the case by his law firm, performed work on it, but ultimately regretted his involvement due to his moral opposition to abortion. Diamantas then asked his superiors to remove him from the case.

Diamantas told Rose he considers himself pro-life, and that he cares deeply about the pro-life cause.

Never miss the latest news in the fight for life.

The abortion pill

Rose also raised the issue of the abortion pill with Diamantas, pointing to an Ethics and Public Policy Center analysis which states that nearly 11% of women who take mifepristone experience serious adverse events.

This is a 22x greater rate than what is listed on the FDA's label for the drug. Rose also noted the sobering death toll of preborn children as a result from the approval and availability of the drug, which is estimated at around 7.5 million lives between 2000 and 2024. Recent estimates from the Guttmacher Institute claim that the abortion pill now makes up at least 65% of all abortions in the U.S. annually.

Diamantas responded by telling Rose that reviewing the abortion pill is a top priority for him and the Trump administration FDA.

The Backstory:

It was announced on May 12 that Marty Makary, who served as FDA Commissioner for 13 months, had resigned from his position amid controversy. As Live Action News previously reported, Makary received criticism from pro-life politicians and advocacy groups for failing to produce a promised review of the abortion drug mifepristone.

As Live Action News also stated, concerns mounted about Acting FDA Commissioner Kyle Diamantas' past involvement with Planned Parenthood in Florida as an attorney in private practice. Diamantas "was appointed as a Senior Counselor and Acting Deputy Commissioner for Human Foods at the FDA by Kennedy in February 2026."

Taking Action:

Rose told Live Action News, “I appreciated the opportunity to speak with Acting FDA Commissioner Kyle Diamantas directly. He was candid about his past work while a junior attorney for Planned Parenthood, his regret over that involvement, his moral opposition to abortion, and his stated commitment to the pro-life cause."

However, she continued:

"Now we need to see action. The FDA must urgently take action on mifepristone, confront the mounting evidence of harm to women, and address the abortion pill regime that has killed millions of preborn children. We and millions of Americans across the nation who value the right to life expect this administration to advance strong pro-life protections for both mothers and their children.”

Live Action News is pro-life news and commentary from a pro-life perspective.

Our work is possible because of our donors. Please consider giving to further our work of changing hearts and minds on issues of life and human dignity.

Contact editor@liveaction.org for questions, corrections, or if you are seeking permission to reprint any Live Action News content.

Guest Articles: To submit a guest article to Live Action News, email editor@liveaction.org with an attached Word document of 800-1000 words. Please also attach any photos relevant to your submission if applicable. If your submission is accepted for publication, you will be notified within three weeks. Guest articles are not compensated (see our Open License Agreement). Thank you for your interest in Live Action News!